Trial Profile
Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Sir-Spheres® for CEA-Expressing Liver Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs CAR-T CEA therapy (Primary) ; Interleukin-2; Yttrium-90
- Indications Adenocarcinoma; Liver metastases
- Focus Adverse reactions
- Acronyms HITM-SIR
- 25 Mar 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2018 Planned End Date changed from 1 Sep 2017 to 1 Jan 2019.
- 28 Mar 2018 According to a Sorrento Therapeutics media release, the Company expects to complete this trial in 2H 2018.